X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Fresenius Kabi Onco. with PLETHICO PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FRESENIUS KABI ONCO. vs PLETHICO PHARMA - Comparison Results

FRESENIUS KABI ONCO.    Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FRESENIUS KABI ONCO. PLETHICO PHARMA FRESENIUS KABI ONCO./
PLETHICO PHARMA
 
P/E (TTM) x 22.1 -1.1 - View Chart
P/BV x 3.1 0.0 18,573.0% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 FRESENIUS KABI ONCO.   PLETHICO PHARMA
EQUITY SHARE DATA
    FRESENIUS KABI ONCO.
Mar-13
PLETHICO PHARMA
Mar-14
FRESENIUS KABI ONCO./
PLETHICO PHARMA
5-Yr Chart
Click to enlarge
High Rs176395 44.6%   
Low Rs7931 250.8%   
Sales per share (Unadj.) Rs37.7604.4 6.2%  
Earnings per share (Unadj.) Rs5.132.5 15.7%  
Cash flow per share (Unadj.) Rs6.751.3 13.1%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs42.5473.6 9.0%  
Shares outstanding (eoy) m158.2334.08 464.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.40.4 957.7%   
Avg P/E ratio x25.06.6 380.8%  
P/CF ratio (eoy) x18.94.2 455.9%  
Price / Book Value ratio x3.00.5 664.7%  
Dividend payout %00-   
Avg Mkt Cap Rs m20,1357,262 277.2%   
No. of employees `0001.2NA-   
Total wages/salary Rs m7031,596 44.1%   
Avg. sales/employee Rs Th5,176.2NM-  
Avg. wages/employee Rs Th610.4NM-  
Avg. net profit/employee Rs Th699.6NM-  
INCOME DATA
Net Sales Rs m5,96320,598 28.9%  
Other income Rs m18386 4.7%   
Total revenues Rs m5,98120,984 28.5%   
Gross profit Rs m1,4302,818 50.8%  
Depreciation Rs m258642 40.2%   
Interest Rs m-261,593 -1.6%   
Profit before tax Rs m1,216969 125.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-680-   
Tax Rs m342-138 -247.3%   
Profit after tax Rs m8061,107 72.8%  
Gross profit margin %24.013.7 175.3%  
Effective tax rate %28.1-14.3 -196.9%   
Net profit margin %13.55.4 251.5%  
BALANCE SHEET DATA
Current assets Rs m5,10218,877 27.0%   
Current liabilities Rs m2,38511,896 20.1%   
Net working cap to sales %45.633.9 134.4%  
Current ratio x2.11.6 134.8%  
Inventory Days Days15036 417.5%  
Debtors Days Days113198 57.3%  
Net fixed assets Rs m5,1489,861 52.2%   
Share capital Rs m158341 46.4%   
"Free" reserves Rs m6,55612,331 53.2%   
Net worth Rs m6,73216,139 41.7%   
Long term debt Rs m9524,706 20.2%   
Total assets Rs m10,38833,146 31.3%  
Interest coverage x-45.81.6 -2,847.0%   
Debt to equity ratio x0.10.3 48.5%  
Sales to assets ratio x0.60.6 92.4%   
Return on assets %7.58.1 92.2%  
Return on equity %12.06.9 174.5%  
Return on capital %14.612.3 118.8%  
Exports to sales %74.521.4 348.4%   
Imports to sales %24.815.2 162.7%   
Exports (fob) Rs m4,4414,402 100.9%   
Imports (cif) Rs m1,4773,136 47.1%   
Fx inflow Rs m5,2984,402 120.3%   
Fx outflow Rs m1,7723,184 55.7%   
Net fx Rs m3,5251,219 289.3%   
CASH FLOW
From Operations Rs m1,2742,437 52.3%  
From Investments Rs m-1,204-6,265 19.2%  
From Financial Activity Rs m-1962,490 -7.9%  
Net Cashflow Rs m-126-1,337 9.4%  

Share Holding

Indian Promoters % 0.0 82.7 -  
Foreign collaborators % 81.0 0.0 -  
Indian inst/Mut Fund % 0.3 4.3 7.0%  
FIIs % 9.6 5.5 174.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 7.5 121.3%  
Shareholders   42,599 10,665 399.4%  
Pledged promoter(s) holding % 0.0 85.7 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FRESENIUS KABI ONCO. With:   SANOFI INDIA  ABBOTT INDIA  STRIDES SHASUN LTD  CIPLA  TORRENT PHARMA  

Compare FRESENIUS KABI ONCO. With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Drops 230 Points as Trade War Fears Resurface(12:30 pm)

After opening the day flat, share markets in India witnessed choppy trading activity throughout the day and are presently below the dotted line.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Should You Get out of Small Caps Now... Before the Fall Worsens(Profit Hunter)

Jun 6, 2018

An almost zero-loss strategy that works best when markets correct. Don't let the current volatility overwhelm you. Focus on the fundamentals and long term, and buy stocks where quality meets value.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

FRESENIUS KABI ONCO. SHARE PRICE


Jan 2, 2014 (Close)

TRACK FRESENIUS KABI ONCO.

  • Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON FRESENIUS KABI ONCO.

FRESENIUS KABI ONCO. 8-QTR ANALYSIS

COMPARE FRESENIUS KABI ONCO. WITH

MARKET STATS